A |
|
Absorption
|
|
Adherence
|
|
Adverse drug event
|
|
Adverse drug reaction
|
|
Affinity
|
|
Agonist
|
|
Allele
|
|
Allosteric modulator
|
|
Allosteric site
|
|
Antagonist
|
|
Apparent volume of distribution (Vd)
|
|
AUC
|
|
B
|
|
Bioavailability (F)
|
|
Biological marker (Biomarker)
|
|
Biotransformation
|
|
C |
|
Cheng-Prusoff equation
|
|
Clinical trials
|
|
Competitve antagonist
|
|
Competitive inhibitor
|
|
Concentration-time curve
|
|
Conformational change
|
|
Constitutive activity
|
|
D |
|
Desensitization
|
|
Dose-response relationships
|
|
Drug clearance
|
|
Drug concentration
|
|
Drug transport
|
|
E |
|
Efficacy
|
|
Enteral drug administration
|
|
Enzyme
|
|
Equilibrium dissociation constant (Kd)
|
|
F |
|
First-pass effect
|
|
Full agonist
|
|
G |
Graded dose-response curve
|
|
H |
|
Half-life
|
|
Haplotype
|
|
I |
|
IC50
|
|
Informed consent document
|
|
Inhibitory constant (Ki)
|
|
Inverse agonist
|
|
Irreversible antagonist
|
|
J |
|
K |
|
L |
|
Ligand
|
|
M |
|
Maximum Activation Potential Vmax
|
|
Metabolic drug tolerance
|
|
Metabolism
|
|
Metabolite
|
|
Michaelis constant (Km)
|
|
N |
|
Non-competitive antagonist
|
|
O |
|
Observational studies
|
|
Orthosteric site
|
|
P |
|
Parent compound
|
|
Parenteral drug administration
|
|
Partial agonist
|
|
Pharmacodynamics
|
|
Pharmacogenetics
|
|
Pharmacogenomics
|
|
Pharmacokinetics (PK)
|
|
Pharmacology
|
|
Phase I Clinical Trial
|
|
Phase II Clinical Trial
|
|
Phase III Clinical Trial
|
|
Phase IV Clinical Trial
|
|
Potency
|
|
Prodrug
|
|
Q |
Quantal dose-response curve
|
|
R |
|
Randomized controlled trials
|
|
Receptor
|
|
Receptor pharmacology
|
|
Reversible antagonist
|
|
S |
|
Side effect
|
|
Spare receptors
|
|
Substrate
|
|
T |
|
Tachyphylaxis
|
|
Therapeutic index
|
|
Therapeutics
|
|
Tolerance
|
|
Toxicology
|
|
Transporter
|
|
U |
|
V |
|
W |
Wild type
|
|
X |
|
Y |
|
Z |
